Bio Rad Labs Inc Financials
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Bio Rad Labs Inc has an operating margin of 1.8%, meaning the company retains $2 of operating profit per $100 of revenue. This below-average margin results in a low score of 9/100, suggesting thin profitability after operating expenses. This is down from 10.5% the prior year.
Bio Rad Labs Inc's revenue declined 100% year-over-year, from $2.6B to $3K. This contraction results in a growth score of 0/100.
Bio Rad Labs Inc carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.62, Bio Rad Labs Inc holds $5.62 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Bio Rad Labs Inc converts 14.5% of revenue into free cash flow ($375). This strong cash generation earns a score of 72/100.
Bio Rad Labs Inc's ROE of 10.2% shows moderate profitability relative to equity, earning a score of 41/100.
Bio Rad Labs Inc scores 1329662.57, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($6.9B) relative to total liabilities ($3K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Bio Rad Labs Inc passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Bio Rad Labs Inc generates $0.70 in operating cash flow ($532 OCF vs $760 net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Bio Rad Labs Inc earns $1.0 in operating income for every $1 of interest expense ($47 vs $49). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Bio Rad Labs Inc (BIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Bio Rad Labs Inc generated $3K in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Bio Rad Labs Inc's EBITDA was $213 in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 100.0% from the prior year.
Bio Rad Labs Inc generated $375 in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 100.0% from the prior year.
Bio Rad Labs Inc reported $760 in net income in fiscal year 2025. This represents an increase of 100.0% from the prior year.
Bio Rad Labs Inc earned $27.85 per diluted share (EPS) in fiscal year 2025. This represents an increase of 142.6% from the prior year.
Bio Rad Labs Inc held $530 in cash against $1K in long-term debt as of fiscal year 2025.
Bio Rad Labs Inc had 22M shares outstanding in fiscal year 2025.
Bio Rad Labs Inc's gross margin was 51.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.9 percentage points from the prior year.
Bio Rad Labs Inc's operating margin was 1.8% in fiscal year 2025, reflecting core business profitability. This is down 8.7 percentage points from the prior year.
Bio Rad Labs Inc's net profit margin was 29.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 101.3 percentage points from the prior year.
Bio Rad Labs Inc's ROE was 10.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Bio Rad Labs Inc invested $276 in research and development in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Bio Rad Labs Inc spent $296 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.
Bio Rad Labs Inc invested $158 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
BIO Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $693.2M+6.2% | $653.0M+0.2% | $651.6M+11.3% | $585.4M-12.3% | $667.5M+2.7% | $649.7M+1.8% | $638.5M+4.5% | $610.8M |
| Cost of Revenue | $348.0M+12.4% | $309.6M+1.1% | $306.3M+9.6% | $279.4M-14.2% | $325.5M+10.8% | $293.8M+3.7% | $283.4M-0.5% | $284.9M |
| Gross Profit | $345.2M+0.5% | $343.4M-0.6% | $345.3M+12.8% | $306.0M-10.5% | $342.0M-3.9% | $355.9M+0.2% | $355.1M+9.0% | $325.9M |
| R&D Expenses | $70.3M-1.4% | $71.3M+17.9% | $60.5M-17.7% | $73.5M-7.7% | $79.6M-12.5% | $91.0M+54.5% | $58.9M-11.3% | $66.4M |
| SG&A Expenses | $221.0M+6.9% | $206.8M-0.4% | $207.7M-0.5% | $208.8M+2.4% | $204.0M+1.8% | $200.4M+2.9% | $194.7M-9.4% | $214.9M |
| Operating Income | -$118.9M-282.1% | $65.3M-15.3% | $77.1M+225.3% | $23.7M-59.4% | $58.4M-9.5% | $64.5M-36.5% | $101.5M+127.6% | $44.6M |
| Interest Expense | $12.1M-1.6% | $12.3M-2.4% | $12.6M+5.0% | $12.0M-1.6% | $12.2M+0.8% | $12.1M-1.6% | $12.3M0.0% | $12.3M |
| Income Tax | $209.2M+334.5% | -$89.2M-192.7% | $96.2M+395.9% | $19.4M+110.0% | -$193.1M-192.7% | $208.4M+133.6% | -$620.8M-679.1% | $107.2M |
| Net Income | $720.0M+310.6% | -$341.9M-207.6% | $317.8M+396.6% | $64.0M+108.9% | -$715.8M-209.6% | $653.2M+130.2% | -$2.2B-664.1% | $383.9M |
| EPS (Diluted) | $26.59+309.4% | $-12.70-208.8% | $11.67+409.6% | $2.29+109.0% | $-25.57-209.6% | $23.34+130.6% | $-76.26-667.0% | $13.45 |
BIO Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.6B+9.1% | $9.7B-5.1% | $10.2B+7.2% | $9.5B+1.7% | $9.4B-11.7% | $10.6B+9.4% | $9.7B-23.2% | $12.6B |
| Current Assets | $2.9B+2.3% | $2.8B+1.1% | $2.8B-7.4% | $3.0B+0.2% | $3.0B-0.8% | $3.1B0.0% | $3.1B-0.2% | $3.1B |
| Cash & Equivalents | $529.8M+33.9% | $395.8M+7.2% | $369.3M-29.2% | $521.4M+6.8% | $488.1M+18.9% | $410.4M+0.9% | $406.9M-6.1% | $433.3M |
| Inventory | $740.7M-5.4% | $783.2M-2.0% | $798.8M+1.1% | $790.1M+4.0% | $760.0M-5.5% | $804.3M+0.1% | $803.7M+2.6% | $783.4M |
| Accounts Receivable | $460.6M-0.9% | $464.7M-1.1% | $469.9M+10.6% | $424.7M-6.1% | $452.5M-2.0% | $461.9M+3.7% | $445.5M+0.2% | $444.8M |
| Goodwill | $579.8M+0.2% | $578.7M-0.5% | $581.6M+40.3% | $414.6M+1.0% | $410.5M-1.1% | $415.1M+0.7% | $412.1M-0.2% | $412.8M |
| Total Liabilities | $3.1B+5.5% | $3.0B-4.1% | $3.1B+8.4% | $2.8B+1.9% | $2.8B-10.3% | $3.1B+7.1% | $2.9B-18.2% | $3.6B |
| Current Liabilities | $517.0M-1.0% | $522.3M-4.8% | $548.9M+8.3% | $506.6M+8.3% | $467.8M-6.1% | $497.9M+2.3% | $487.0M+4.5% | $466.2M |
| Long-Term Debt | $1.2B0.0% | $1.2B0.0% | $1.2B0.0% | $1.2B0.0% | $1.2B0.0% | $1.2B0.0% | $1.2B0.0% | $1.2B |
| Total Equity | $7.5B+10.6% | $6.7B-5.5% | $7.1B+6.7% | $6.7B+1.7% | $6.6B-12.3% | $7.5B+10.5% | $6.8B-25.1% | $9.1B |
| Retained Earnings | $8.2B+9.7% | $7.5B-4.4% | $7.8B+4.2% | $7.5B+0.9% | $7.4B-8.8% | $8.1B+8.7% | $7.5B-22.5% | $9.6B |
BIO Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $164.9M+36.4% | $120.9M+3.8% | $116.5M-10.3% | $129.9M+4.6% | $124.2M-24.1% | $163.6M+67.6% | $97.6M+39.8% | $69.8M |
| Capital Expenditures | $45.8M+44.5% | $31.7M-30.6% | $45.7M+32.8% | $34.4M-19.8% | $42.9M+6.7% | $40.2M-5.0% | $42.3M+5.2% | $40.2M |
| Free Cash Flow | $119.1M+33.5% | $89.2M+26.0% | $70.8M-25.9% | $95.5M+17.5% | $81.3M-34.1% | $123.4M+123.1% | $55.3M+86.8% | $29.6M |
| Investing Cash Flow | -$34.2M+20.5% | -$43.0M+62.7% | -$115.4M-4079.3% | $2.9M+109.5% | -$30.5M+45.2% | -$55.7M-80.3% | -$30.9M+28.3% | -$43.1M |
| Financing Cash Flow | $3.3M+106.3% | -$52.5M+61.5% | -$136.3M-39.5% | -$97.7M-272.9% | -$26.2M+72.7% | -$96.0M+0.6% | -$96.6M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0-100.0% | $53.4M-61.9% | $140.2M+37.6% | $101.9M | $0-100.0% | $97.9M-3.1% | $101.0M+2048.9% | $4.7M |
BIO Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.8%-2.8pp | 52.6%-0.4pp | 53.0%+0.7pp | 52.3%+1.0pp | 51.2%-3.5pp | 54.8%-0.8pp | 55.6%+2.3pp | 53.4% |
| Operating Margin | -17.2%-27.2pp | 10.0%-1.8pp | 11.8%+7.8pp | 4.0%-4.7pp | 8.8%-1.2pp | 9.9%-6.0pp | 15.9%+8.6pp | 7.3% |
| Net Margin | 103.9%+156.2pp | -52.4%-101.1pp | 48.8%+37.8pp | 10.9%+118.2pp | -107.2%-207.8pp | 100.5%+439.7pp | -339.2%-402.0pp | 62.8% |
| Return on Equity | 9.7% | N/A | 4.5%+3.5pp | 1.0% | N/A | 8.7% | N/A | 4.2% |
| Return on Assets | 6.8%+10.3pp | -3.5%-6.6pp | 3.1%+2.4pp | 0.7%+8.3pp | -7.6%-13.8pp | 6.2%+28.5pp | -22.4%-25.4pp | 3.0% |
| Current Ratio | 5.62+0.2 | 5.44+0.3 | 5.12-0.9 | 5.99-0.5 | 6.48+0.3 | 6.14-0.1 | 6.28-0.3 | 6.57 |
| Debt-to-Equity | 0.16-0.0 | 0.180.0 | 0.17-0.0 | 0.180.0 | 0.18+0.0 | 0.16-0.0 | 0.18+0.0 | 0.13 |
| FCF Margin | 17.2%+3.5pp | 13.7%+2.8pp | 10.9%-5.4pp | 16.3%+4.1pp | 12.2%-6.8pp | 19.0%+10.3pp | 8.7%+3.8pp | 4.9% |
Similar Companies
Frequently Asked Questions
What is Bio Rad Labs Inc's annual revenue?
Bio Rad Labs Inc (BIO) reported $3K in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bio Rad Labs Inc's revenue growing?
Bio Rad Labs Inc (BIO) revenue declined by 100% year-over-year, from $2.6B to $3K in fiscal year 2025.
Is Bio Rad Labs Inc profitable?
Yes, Bio Rad Labs Inc (BIO) reported a net income of $760 in fiscal year 2025, with a net profit margin of 29.4%.
What is Bio Rad Labs Inc's earnings per share (EPS)?
Bio Rad Labs Inc (BIO) reported diluted earnings per share of $27.85 for fiscal year 2025. This represents a 142.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Bio Rad Labs Inc's EBITDA?
Bio Rad Labs Inc (BIO) had EBITDA of $213 in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Bio Rad Labs Inc have?
As of fiscal year 2025, Bio Rad Labs Inc (BIO) had $530 in cash and equivalents against $1K in long-term debt.
What is Bio Rad Labs Inc's gross margin?
Bio Rad Labs Inc (BIO) had a gross margin of 51.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bio Rad Labs Inc's operating margin?
Bio Rad Labs Inc (BIO) had an operating margin of 1.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Bio Rad Labs Inc's net profit margin?
Bio Rad Labs Inc (BIO) had a net profit margin of 29.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Bio Rad Labs Inc's return on equity (ROE)?
Bio Rad Labs Inc (BIO) has a return on equity of 10.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bio Rad Labs Inc's free cash flow?
Bio Rad Labs Inc (BIO) generated $375 in free cash flow during fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bio Rad Labs Inc's operating cash flow?
Bio Rad Labs Inc (BIO) generated $532 in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bio Rad Labs Inc's total assets?
Bio Rad Labs Inc (BIO) had $11K in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bio Rad Labs Inc's capital expenditures?
Bio Rad Labs Inc (BIO) invested $158 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Bio Rad Labs Inc spend on research and development?
Bio Rad Labs Inc (BIO) invested $276 in research and development during fiscal year 2025.
Does Bio Rad Labs Inc buy back shares?
Yes, Bio Rad Labs Inc (BIO) spent $296 on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
How many shares does Bio Rad Labs Inc have outstanding?
Bio Rad Labs Inc (BIO) had 22M shares outstanding as of fiscal year 2025.
What is Bio Rad Labs Inc's current ratio?
Bio Rad Labs Inc (BIO) had a current ratio of 5.62 as of fiscal year 2025, which is generally considered healthy.
What is Bio Rad Labs Inc's debt-to-equity ratio?
Bio Rad Labs Inc (BIO) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bio Rad Labs Inc's return on assets (ROA)?
Bio Rad Labs Inc (BIO) had a return on assets of 7.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bio Rad Labs Inc's Altman Z-Score?
Bio Rad Labs Inc (BIO) has an Altman Z-Score of 1329662.57, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bio Rad Labs Inc's Piotroski F-Score?
Bio Rad Labs Inc (BIO) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bio Rad Labs Inc's earnings high quality?
Bio Rad Labs Inc (BIO) has an earnings quality ratio of 0.70x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bio Rad Labs Inc cover its interest payments?
Bio Rad Labs Inc (BIO) has an interest coverage ratio of 1.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Bio Rad Labs Inc?
Bio Rad Labs Inc (BIO) scores 54 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.